Opdivo/Yervoy combo flops again in melanoma, but Bristol Myers Squibb also has a new OK to celebrate
Bristol Myers Squibb’s Opdivo/Yervoy combo regimen has officially failed both co-primary endpoints in a trial testing it as an adjuvant therapy for melanoma.
Adding Yervoy, the CTLA4 inhibitor, to the PD-1 antibody Opdivo failed to induce a statistically significant improvement in recurrence-free survival among the all-comer population, the pharma giant reported. The news comes almost one year after Bristol Myers conceded that the pairing didn’t help patients with very low levels of PD-L1 — who would theoretically be less likely to benefit from Opdivo — any more than the Opdivo alone did.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
